Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
| Autor: | Marco Merlo, Claudio Rapezzi, Gianfranco Sinagra, Aldostefano Porcari |
|---|---|
| Přispěvatelé: | Porcari, Aldostefano, Merlo, Marco, Rapezzi, Claudio, Sinagra, Gianfranco |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Grey zone Disease Review Article 030204 cardiovascular system & hematology Cardiac amyloidosis Transthyretin NO 03 medical and health sciences 0302 clinical medicine Cardiac amyloidosi Epidemiology Internal Medicine medicine Humans Prealbumin Disease-modifying therapies 030212 general & internal medicine Disease-modifying therapie Intensive care medicine Prognostic stratification Heart Failure biology Horizon (archaeology) business.industry Heart Amyloidosis medicine.disease Grey zones Natural history Heart failure biology.protein Amyloid cardiomyopathy business Cardiomyopathies |
| Zdroj: | European Journal of Internal Medicine |
| Popis: | Highlights • Transthyretin amyloid cardiomyopathy (ATTR-AC) is an under-diagnosed disease. • Many grey areas are emerging in clinical management and prognostic stratification. • Candidates’ selection for novel drugs is crucial, but response criteria are lacking. • The impact of evidence-based therapies for HF in ATTR-AC should be investigated. • Multidisciplinary team is the way to deliver the best clinical management. Transthyretin amyloid cardiomyopathy (ATTR-AC) is an under-recognized and underdiagnosed disease. Although traditionally considered a rare condition, the epidemiology of the disease is rapidly changing due to the possibility of non-invasive diagnosis through cardiac scintigraphy with bone tracers and novel disease-modifying treatments providing survival advantages. Nevertheless, many questions and grey areas have to be addressed, such as the natural history of ATTR-AC, the role and implications of genotype–phenotype interactions, the best clinical management, prognostic stratification and the most appropriate treatments, including those already recommended for patients with heart failure. Clinicians have to cope with old beliefs and evolving concepts in ATTR-AC. A wide horizon of possibilities for physicians of many specialties is unfolding and awaits discovery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|